NEU — Neuren Pharmaceuticals Cashflow Statement
0.000.00%
- AU$2.57bn
- AU$2.27bn
- AU$224.26m
- 80
- 57
- 90
- 89
Annual cashflow statement for Neuren Pharmaceuticals, fiscal year end - December 31st, AUD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | -0.725 | 0.819 | -1.23 | 0.081 | 7.15 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -8.08 | -9.97 | 3.6 | 185 | -11.3 |
| Capital Expenditures | -0.006 | -0.01 | -0.019 | -0.04 | -0.01 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | — | -211 | 4.14 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.006 | -0.01 | -0.019 | -211 | 4.13 |
| Financing Cash Flow Items | -1.07 | -1.11 | -0.002 | -0.018 | -0.009 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 19.1 | 22.2 | -0.002 | 3.62 | -8.78 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 10.3 | 12.6 | 3.4 | -23.1 | -13.9 |